Comprehensive Information on Yaz Birth Control Warnings and Legal News Added to DrugRisk Resource Site

Share Article

The Drug Resource Center is the Web’s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com

DrugRisk Dangerous Drugs
Anyone who suffered a blood clot, DVT, stroke or Pulmonary Embolism after taking Yaz or Yasmin is urged to contact the Drug Risk Resource Center or speak with a lawyer about their legal options.

Online prescription drug and medical device resource center DrugRisk has added information about the latest side effect warnings and legal settlements related to the birth control drugs Yaz and Yasmin to its existing data on the most popular medications and devices.

“The goal of the DrugRisk Resource Center has always been to improve public safety by providing the latest updates on prescription drug warnings, recalls, studies and litigation. We continue this with up-to-date information on the birth control drugs Yaz and Yasmin,’ said DrugRisk representative Ryan Mayer.

The added information includes a recently published warning by the American College of Obstetricians and Gynecologists that birth control pills containing drospirenone, such as Yaz and Yasmin, may have a higher risk of causing blood clots.*

DrugRisk also tracks financial reports from prescription drug makers disclosing pending legal issues. Bayer recently reported that they continue to settle claims that Yaz and Yasmin caused blood clots, indicating they have settled approximately 3,500 Yaz lawsuits so far at a total cost of nearly $750 million, or an average of approximately $214,000 per case.**

The company also confirmed they are only settling claims involving blood clot injuries, such as deep vein thrombosis and pulmonary embolism.

Anyone who suffered a blood clot, DVT, stroke or Pulmonary Embolism after taking Yaz or Yasmin is urged to contact the Drug Risk Resource Center or speak with a lawyer about their legal options.

DrugRisk contains previously issued information on Yaz and Yasmin as well. On October 25, 2011, the British Medical Journal published a study from the University of Copenhagen linking the hormone in Yaz to blood clots. On October 27, 2011, the FDA also released a study entitled "Combined Hormonal Contraceptives and the Risk of Cardiovascular Disease Endpoints" showing drugs like Yaz could increase the risk of blood clots, DVT and pulmonary embolism by as much as 74%.

DrugRisk has learned that the volume of Yaz lawsuits have been consolidated to a special federal Multi-District Litigation court in Illinois. The formal case is known as Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois).

The Drug Risk Resource Center cautions victims who wish to learn about their legal options that they should seek a lawyer with experience in defective drug litigation, and only recommends lawyers and law firms who have already settled Yaz lawsuits.

For more information on the research, side effects and litigation news and other drugs, or to speak with a Yaz lawyer, visit http://www.DrugRisk.com.

*Chicago Tribune October 24, 2012, “Newer Pill has low blood clot risk: ob-gyn group”
**Bayer Interim Financial Statement, Legal Notes and Business Development, September 30, 2012

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Patient Advocate
DrugRisk
888-415-1859
Email >
Visit website